Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Aaron C Tan,1 Tracy J Loh,2 Xue Lin Kwang,1 Gek San Tan,2 Kiat Hon Lim,2 Daniel SW Tan1 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore; 2Department of Pathology, Singapore General Hospital, Singapore, 169608, SingaporeCorrespondence: Daniel SW TanNation...
Enregistré dans:
Auteurs principaux: | Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/031f63eddb764d4ebbf865c25b2d833d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
par: Guo MZ, et autres
Publié: (2021) -
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
par: Fujino T, et autres
Publié: (2021) -
Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa
par: Franciscus C. Vermeer, et autres
Publié: (2021) -
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
par: Zhang SS, et autres
Publié: (2021) -
Case Report: A Synonymous Mutation in NF1 Located at the Non-canonical Splicing Site Leading to Exon 45 Skipping
par: Pengzhen Jin, et autres
Publié: (2021)